Claims for Patent: 5,455,240

Summary for Patent: 5,455,240

Title:	Modulators of pneumococcal adhesion to cellular targets involving the platelet activating factor receptor, and uses thereof
Abstract:	The present invention relates to compositions and methods for preventing pneumococcal infection. In particular, the invention relates to identification of the major reception for Streptococcus pneumoniae on activated human cells, and diagnostic and therapeutic compositions and methods based thereon. In particular, the invention relates to the discovery that platelet activating factor (PAF) receptor is an adhesive ligand for pneumococcal adherence to activated lung epithelial and venous endothelial (i.e., host) cells. Accordingly, the present invention is directed to a method for preventing or treating an infection with Streptococcus pneumoniae by administering an antagonist of platelet activating factor receptor. The invention further relates to recognition that adherence to activated cells also involves a carbohydrate ligand found on such activated cells. Thus, a method for inhibiting pneumococcal adherence may further comprise administering an amount of carbohydrate containing an N-acetyl-D-glucosamine motif. It has been found that resting lung epithelial and venous endothelial cells bear two classes of receptors containing different carbohydrate motifs. Thus, the invention further provides for administering an amount of a second carbohydrate selected from the group consisting of a carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-4Gal motif, a disaccharide N-acetyl-D-galactosamine .beta.1-3Gal motif, and a mixture thereof. In addition, the invention provides pharmaceutical compositions comprising such agents that inhibit binding of pneumococci to human cells. In a specific example, platelet activating factor receptor antagonists and disaccharides are shown to inhibit binding of pneumococci to activated lung epithelial cells and venous endothelial cells, as well as cells transfected with the platelet activating factor receptor, in vitro.
Inventor(s):	Tuomanen; Elaine I. (New York, NY), Cundell; Diana R. (New York, NY), Gerard; Norma P. (Dover, MA)
Assignee:	The Rockefeller University (New York, NY) Beth Israel Hospital Association (Boston, MA)
Application Number:	08/262,306
Patent Claims:	1. A method for preventing or treating an infection with Streptococcus pneumoniae comprising administering to a subject believed to be in need of such treatment an amount of an antagonist of platelet activating factor receptor effective to inhibit binding of S. pneumoniae to host cells. 2. The method according to claim 1, further comprising administering an amount of carbohydrate containing an N-acetyl-D-glucosamine motif effective to inhibit binding of S. pneumoniae to host cells. 3. The method according to claim 2, further comprising administering an amount of a second carbohydrate selected from the group consisting of a carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-4Gal motif, a disaccharide N-acetyl-D-galactosamine .beta.1-3Gal motif, and a mixture thereof, effective to inhibit binding of S. pneumoniae to host cells. 4. The method according to claim 1, in which the antagonist of platelet activating factor receptor is selected from the group consisting of L659,989, L652,731, WEB 2086, kadsurenone, and FR72112. 5. The method according to claim 2, in which the carbohydrate is N-acetyl-D-glucosamine. 6. The method according to claim 3, in which the second carbohydrate is selected from the group consisting of forssman glycolipid, globoside, asialo-GM1 and asialo-GM2. 7. The method according to claim 1, 2, or 3, further comprising administering an amount of a carbohydrate selected from the group consisting of mannose, N-acetyl-galactose, mannose-D-mannose, and methyl-.alpha.-D-mannopyranoside effective to inhibit binding of S. pneumoniae to host cells. 8. The method according to claim 2 or 3, in which the carbohydrate or carbohydrates are multivalent. 9. The method according to claim 1, 2, or 3, in which the administering comprises atomizing and inhaling. 10. The method according to claim 9, in which the atomizing is nebulizing. 11. The method according to claim 1, 2, or 3, in which the administering comprises injecting intravenously. 12. The method according to claim 1, further comprising administering an inhibitor of inflammation effective to inhibit expression of platelet activating factor receptor. 13. The method according to claim 12, wherein the inhibitor of inflammation is selected from the group consisting of a neutralizing antibody to tumor necrosis factor, a neutralizing soluble tumor necrosis factor receptor, a neutralizing antibody to interleukin-1, and a neutralizing soluble interleukin-1 receptor. 14. A pharmaceutical composition comprising an amount of a platelet activating factor receptor antagonist effective to inhibit binding of S. pneumoniae to host cells, an amount of a carbohydrate containing an N-acetyl-D-glucosamine motif effective to inhibit binding of S. pneumoniae to host cells, and a pharmaceutically acceptable carrier. 15. The pharmaceutical composition of claim 14, further comprising an amount of a carbohydrate selected from the group consisting of a carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-3Gal motif and a carbohydrate containing a disaccharide N-acetyl-D-galactosamine .beta.1-4Gal motif effective to inhibit binding of S. pneumoniae to host cells. 16. The pharmaceutical composition of claim 14, in which the antagonist of platelet activating factor receptor is selected from the group consisting of L659,989, L652,731, WEB 2086, kadsurenone, and FR72112. 17. The pharmaceutical composition of claim 14, in which the carbohydrate is N-acetyl-D-glucosamine. 18. The pharmaceutical composition of claim 15, in which the second carbohydrate is selected from the group consisting of forssman glycolipid, globoside, asialo-GM1 and asialo-GM2. 19. The pharmaceutical composition of claim 14 or 15, further comprising an amount of a carbohydrate selected from the group consisting of mannose, N-acetyl-galactose, mannose-D-mannose, and methyl-.alpha.-D-mannopyranoside effective to inhibit binding of S. pneumoniae to host cells. 20. The pharmaceutical composition according to claim 14 or 15, in which the carbohydrate or carbohydrates are multivalent. 21. The pharmaceutical composition of claim 14 or 15, in which the pharmaceutical composition is an aerosol formulation, which formulation contains a dispersant. 22. The pharmaceutical composition of claim 21, in which the dispersant is a surfactant. 23. The pharmaceutical composition of claim 21, which is a dry powder aerosol formulation, in which the carbohydrate or carbohydrates are present in finely divided powder. 24. The pharmaceutical composition of claim 23, which further comprises a bulking agent. 25. The pharmaceutical composition of claim 21, which is a liquid aerosol formulation further comprising a pharmaceutically acceptable diluent. 26. The pharmaceutical composition of claim 25, in which the diluent is selected from the group consisting of sterile water, saline, buffered saline, and dextrose solution. 27. The pharmaceutical composition of claim 14 or 15, in which the host cell is selected from the group consisting of lung epithelial cells and vascular endothelial cells.

Details for Patent 5,455,240

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23